By Gloria Guillo on October 19, 2025
In Nicaragua, where children often need to be treated for parasite infections, a treatment with albendazole costs around 10¢. In the US, parasitic infections are increasing it costs $380.
In The Graduate (1967), a family friend corners young Benjamin Braddock with one word of advice for his future: “Plastics.” It was a nod to a booming, transformative industry—lucrative, ubiquitous, and shaping modern life. Today, a new contender emerges in the pharmaceutical realm: anti-parasitical drugs like albendazole. These medications, critical for treating parasitic infections, are gaining prominence not only for their traditional uses but also for novel applications against viruses and cancer, positioning them as a medical “plastic” of our era—valuable, versatile, yet mired in controversy due to stark pricing disparities. In the U.S., a single 400 mg dose of albendazole can cost over US$380, while in Nicaragua, the same dose is mere pennies. This contrast reveals a U.S. system driven by profit over public health, exacerbated by emerging dietary trends like insect-based foods that heighten parasite risks. This article explores albendazole’s rising importance, contrasts its pricing between the U.S. and Nicaragua, and critiques how market dynamics exploit a drug poised to redefine medicine.
Albendazole’s Rising Value: The New “Plastic”
Albendazole, a broad-spectrum antiparasitic, treats infections like hookworm, pinworm, ascariasis, neurocysticercosis, and hydatid disease. Included on the World Health Organization’s List of Essential Medicines, it is a cornerstone for global health, especially in tropical regions where parasitic diseases are endemic. But its value is soaring due to emerging applications beyond parasites. Recent studies show albendazole inhibits viral replication in diseases like hepatitis C and dengue, with clinical trials exploring its potential against HIV. In oncology, it disrupts microtubule formation in cancer cells, showing promise in colorectal and lung cancer models, with phase II trials underway. These uses elevate albendazole’s status, making it a versatile asset akin to plastics in The Graduate—a game-changer with vast potential.
Yet, this potential is overshadowed by a darker trend: the push for insect-based foods. Promoted as sustainable protein sources, insects like crickets and mealworms are gaining traction, with the global edible insect market projected to reach US$7.96 billion by 2030. Initiatives like the EU’s Novel Foods Regulation and U.S. startups advocate for insect consumption to combat climate change. However, insects can harbor parasites like tapeworms and protozoa, transmissible to humans if improperly processed. A 2023 study found that 30% of farmed crickets carried parasitic larvae, raising risks as consumption scales. This trend amplifies the need for drugs like albendazole, yet access is starkly unequal.
U.S. Pricing: A Profit-Driven Crisis
In the U.S., albendazole’s retail price for a standard course (two 200 mg tablets) can exceed US$700 without insurance, though discounts via GoodRx or SingleCare drop it to US$24–$33. This is astronomical compared to Nicaragua, where a 400 mg dose costs about 4¢ to 10¢, reflecting subsidized generics and government price controls. The U.S. price surge, despite albendazole being off-patent since the 1990s, stems from market dynamics rather than production costs, which are minimal globally (Health Affairs).
In 2010, GlaxoSmithKline sold U.S. rights to CorePharma; then it was bought by Amedra Pharmaceuticals (private equity-backed), and finally Impax Laboratories (now Amneal). This created a near-monopoly, with Impax as the sole supplier. A manufacturing pause triggered FDA shortages, blocking generic competitors due to bioequivalence rules. Prices soared from US$6 per dose in 2010 to US$190+ per tablet today—an 8,000% hike (Kaiser Health News). Low U.S. demand (e.g., pinworms affect ~10% of children yearly; hookworm cases are rare but rising) discourages new manufacturers, as market entry costs outweigh profits. Unlike Nicaragua’s state-driven model, the U.S.’s fragmented system—where insurers must cover FDA-approved drugs—enables “rent-seeking,” with companies exploiting niche markets (Brookings).
This mirrors broader trends: mebendazole (another antiparasitic) jumped 8,000% to US$430/dose, and praziquantel rose 500% (KFF). Private equity’s role prioritizes short-term gains, and FDA barriers during shortages stifle competition. For clinics serving immigrants or refugees, where parasitic infections are more common, 15% now skip screening asymptomatic patients due to costs, risking incomplete treatment (New England Journal of Medicine).
Nicaragua: Pennies for Health Equity
In contrast, Nicaragua’s albendazole pricing—4¢ to 10¢ per 400 mg dose—reflects a health system prioritizing access over profit. The Sandinista government, since 2007, has expanded public healthcare, subsidizing generics through partnerships with Latin American manufacturers like Cuba’s Labiofam. Programs like the WHO’s mass drug administration for soil-transmitted helminths ensure free or low-cost albendazole for rural communities, where 60% of Nicaraguans face parasitic risks. Price controls and bulk procurement keep costs down, unlike the U.S.’s market-driven model. Nicaragua’s approach, rooted in socialized medicine, delivers albendazole at a fraction of U.S. prices, even as its GDP per capita (US$2,255 in 2024) is dwarfed by the U.S.’s (US$81,000) (World Bank).
This disparity highlights systemic priorities. Nicaragua’s model, while not perfect—rural access gaps persist—ensures affordability, aligning with global health equity goals. The U.S., by contrast, allows unchecked price hikes, with insurers and patients bearing the cost. For a drug now critical against viruses and cancer, and increasingly vital as insect-based diets raise parasite risks, this inequity is stark.
Insect Foods and Parasite Risks
The global push for insect consumption amplifies albendazole’s importance. The UN’s Food and Agriculture Organization promotes insects as sustainable, with North American startups like Aspire Food Group scaling cricket farming. Yet, insects carry parasites—tapeworms, flukes, and protozoa—transmissible if undercooked or poorly sourced. A 2024 study found 28% of market-sold mealworms harbored parasitic larvae, and improper farming hygiene increases risks. As insect foods enter mainstream diets (e.g., cricket flour in U.S. protein bars), demand for antiparasitics like albendazole could surge, especially in the U.S., where screening and treatment costs are prohibitive.
The Broader Implications: Profit vs. People
Albendazole’s U.S. pricing reflects a system where profit trumps need, unlike Nicaragua’s equitable model. The drug’s new roles—against viruses, cancer, and emerging parasite risks from insect diets—make it the “plastic” of modern medicine: transformative, indispensable, yet hoarded by market forces. In The Graduate, plastics symbolized opportunity; today, albendazole’s inaccessibility symbolizes greed. Its 8,000% price hike mirrors hikes in generics like insulin (up 1,200% since 2002). The U.S. military health system, facing similar anthelmintic cost spikes, shifted to over-the-counter pyrantel pamoate (US$15–US$20) for pinworms.
Solutions exist: nonprofit generics like Civica Rx, FDA reforms for faster approvals, or importing low-cost albendazole from countries like Nicaragua. Patient assistance programs or coupons help, but gaps remain for the uninsured. For now, patients can use GoodRx to save up to 97% or explore alternatives like pyrantel, though less effective for complex infections. Nicaragua’s model—pennies for a dose—shows what’s possible when health trumps profit.
Conclusion: A Call for Equity
Albendazole, the new “plastic,” is poised to reshape medicine with its antiviral and anticancer potential, yet its U.S. price—$700 versus Nicaragua’s pennies—exposes a system prioritizing wealth over lives. As insect-based foods raise parasite risks, affordable access becomes critical. Nicaragua’s approach, rooted in public health, contrasts sharply with U.S. market failures. Like Benjamin Braddock rejecting plastics’ hollow promise, we must demand a system where life-saving drugs aren’t luxuries. Equity, not exploitation, must define this new era.
Gloria Guillo is an investigative reporter who has covered elections in Nicaragua, Venezuela and Brazil.